$DRTS

3 theses
bullish 100%neutral 0%bearish 0%
Avg return (3d)
+2.9%
Win rate (3d)
33% (3 resolved)

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices delayed ~15 min · refreshed 2m ago
$DRTSr/wallstreetbetsDDbullish
u/passionlessDrone · 45d agono track record yet
Long 3,500 shares of DRTS

DRTS - Cancer Goes Bye Bye / Portfolio Goes High High

DRTS uses radium-224 alpha particles to attack tumors directly regardless of genetic markers or protein expression, demonstrating impressive early results in glioblastoma, pancreatic, and skin cancers. The company has FDA breakthrough device designation and regulatory advantage as a device rather than drug, with significant market value potential if the technology proves durable and scalable across multiple solid tumor types.

At post $14.89Now $12.10-18.7% since posted2m ago
1d—
3d-4.3%
1w-3.2%
1m-9.1%
3m—
6m—
1y—
original post →
$DRTSr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish
u/Pristine_Hurry_4693 · 344d ago2 prior · 100% at 3mo

This should be the main news on CNBC today, don’t miss this play just because it’s under the radar! [DRTS]

Alpha Tau's revolutionary cancer treatment achieved first-ever successful GBM (glioblastoma) patient treatment with FDA Breakthrough Device Designation. The company's platform has proven efficacy across multiple solid tumors and holds ~$350M market cap with significant upside potential as awareness grows and additional catalysts (e.g., PMDA approval in Japan) materialize.

At post $4.23Now $12.10+186.0% since posted2m ago
1d+19.6%
3d+19.4%
1w+21.5%
1m+51.5%
3m+58.6%
6m+121.0%
1y—
original post →
$DRTSr/pennystocksBullishbullish
u/Pristine_Hurry_4693 · 371d ago2 prior · 100% at 3mo

Why were both the CEO and CFO secretly in Tokyo at the same time?

DRTS is developing a revolutionary cancer treatment approaching PMDA approval in Japan before year-end, with both CEO and CFO's presence suggesting serious commercialization progress. The company has FDA breakthrough designation, all necessary capital, strong phase 2/3 results, and a tiny market cap in a massive market with virtually no retail awareness, positioning it as a multi-bagger opportunity.

At post $3.97Now $12.10+204.8% since posted2m ago
1d-2.6%
3d-6.4%
1w-7.3%
1m+27.2%
3m+85.4%
6m+160.5%
1y+236.5%
original post →

End of results.